Hypothetical: Cytodyn's CD-12 results came back to
Post# of 153822
(Total Views: 529)
Posted On: 02/22/2021 5:11:25 PM
Hypothetical: Cytodyn's CD-12 results came back to Nader Pourhassan on Friday and the results were out of the park, somewhere between a Home Run and a Grand Slam Home Run. You are Dr. Pourhassan, what would you do?
I am looking for legitimate responses here. I am trying to figure out why what I view as the only thing that Dr. Pourhassan could do, other than the full release of the basic top line data, dropped the stock so much or at all. I want to know why anyone could have thought the PR was bad in any way.
More facts for hypothetical: The company Cytodyn is a little OTC company located in Washington State. They have only relatively few employees, and they do not have any media department per se.
Using those additional facts, here are two bonus questions: Had Dr. Pourhassan released the full top line data and it was a Home Run to a Grand Slam Home Run, what would have happened today? Not just talking about the share price, but the media, etc. Could CytoDyn have handled the media onslaught along with delicate negotiations with the FDA, and presumably distribution discussions, at the same time?
What am I missing here? Someone explain why it went down, addressing the above. Thank you.
I am looking for legitimate responses here. I am trying to figure out why what I view as the only thing that Dr. Pourhassan could do, other than the full release of the basic top line data, dropped the stock so much or at all. I want to know why anyone could have thought the PR was bad in any way.
More facts for hypothetical: The company Cytodyn is a little OTC company located in Washington State. They have only relatively few employees, and they do not have any media department per se.
Using those additional facts, here are two bonus questions: Had Dr. Pourhassan released the full top line data and it was a Home Run to a Grand Slam Home Run, what would have happened today? Not just talking about the share price, but the media, etc. Could CytoDyn have handled the media onslaught along with delicate negotiations with the FDA, and presumably distribution discussions, at the same time?
What am I missing here? Someone explain why it went down, addressing the above. Thank you.
(0)
(0)